Navigation Links
Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis

TORONTO, April 7 /PRNewswire/ - Medical Futures Inc. has licensed MUTAFLOR(R) for the North American market. MUTAFLOR(R) is a drug used in remission maintenance of Ulcerative Colitis. Since its discovery in 1917, MUTAFLOR(R) has been available in the German marketplace through a subsidiary of Pharma-Zentrale GmbH, Ardeypharm GmbH. MUTAFLOR(R) has shown clinical efficacy in phase III clinical trials and has shown a perfect safety record since 1917. Ulcerative colitis is an Inflammatory Bowel Disease that affects 500,000 Americans and 60,000 Canadians.

"Medical Futures Inc. is excited about partnering with Pharma-Zentrale GmbH for MUTAFLOR(R)," says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that MUTAFLOR(R) will help improve the options available for Ulcerative Colitis patients.

"Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in North America," says Hans Proppert, President and Chief Executive Officer of Pharma Zentrale GmbH. "With MUTAFLOR(R) in their capable hands, we are confident of its success in an important market for us."


MUTAFLOR(R) has data proving equal efficacy when compared to 5-ASA products in remission maintenance of Ulcerative Colitis. It is taken as an oral capsule format that saves patients from intravenous infusions or self administration of subcutaneous needles. This, together with the clinical evidence, is one advantage of MUTAFLOR(R) over all other biologics available on the market.

About Medical Futures Inc.

Medical Futures Inc. is a niche pharmaceutical company that has a focus on gastrointestinal therapy. Medical Futures is dedicated to improving quality of life and provides safe, effective and affordable medicines. These medicines include:

Florastor(TM): The world's number one probiotic that has proven efficacy in treating and preventing diarrhea from various causes including Pediatric Diarrhea, Antibiotic Associated, Clostridium Difficile and Travellers' Diarrhea.

Iberogast(R): The only treatment available for Non-ulcer Dyspepsia and Irritable Bowel Syndrome.

Zingo(TM) is a needle-free, easy-to-administer, single-use system that delivers sterile lidocaine powder into the epidermis of the skin that provides topical, local analgesia in one minute.

SANVAR(R) is the only somatostatin analogue to have demonstrated statistically significant benefits in the treatment of esophageal variceal bleeding in association with endoscopic therapy in a placebo-controlled clinical study (NEJM, 2001).

SOURCE Medical Futures Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: